A potent METTL3 selective inhibitor (UZH2, METTL3 IC50 = 5 nM) has certain inhibitory activity in the MOLM-13 cells (EC50 = 0.7 μM) and prostate cancer cells (EC50 = 2.5 μM) [132]. Here, METTL3 is linked to prostate carcinoma.